Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
filingDate |
2013-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b722bf3c294e3bdf420c064423a6c0e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ab74dae596e3914a53ebebdfb3cf762 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e26fe0e62951a2ab5984483361323fd1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81a3b84bf4e44c9a34f150a1412b9b8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d73f723c6a3e8500ae2f106b26e50cc3 |
publicationDate |
2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11052128-B2 |
titleOfInvention |
Formulation for bispecific T-cell engagers (BiTEs) |
abstract |
The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions. |
priorityDate |
2012-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |